Clinical Trial Update: Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a conditioning regimen of busulfan, melphalan, and thiotepa followed by donor stem cell transplant in patients with high-risk Ewing sar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma

Drugs mentioned

• BUSULFAN (Busulfan)
• Melphalan (Melphalan)
• THIOTEPA (THIOTEPA)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2015-11-25